Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of Life (QoL) using EORTC QoL-C30 and BN20 among Patients who Underwent Brain Tumor Resection in a Tertiary Care Center in Saudi Arabia.

The Gulf journal of oncology·2026
Same author

Internal carotid artery agenesis: A narrative review.

Surgical neurology international·2026
Same author

Fluoroscopy-guided surgical retrieval of a retained intradural spinal catheter following major aortic surgery.

Surgical neurology international·2026
Same author

Clinical Discovery and Molecular Analysis of Two Novel MSH2 Gene Mutations (p.Ala771Gly and p.Val797Gly) in Saudi Colorectal Cancer Patients: Potential Implications for Tumorigenesis.

Health science reports·2026
Same author

A combined transcriptomic, epigenetic, and functional analysis identifies novel biomarkers in breast cancer.

Hereditas·2025
Same author

Pulmonary artery intimal sarcoma with aberrant cytokeratin expression; a rare and challenging event in surgical pathology with ambiguous clinical presentation. a case report and literature review.

Journal of cardiothoracic surgery·2025

Related Experiment Video

Updated: Mar 22, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.0K

Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.

Hans-Juergen Schulten1,2, Deema Hussein3, Fatima Al-Adwani1,4

  • 1Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.

Plos One
|April 21, 2016
PubMed
Summary

Deleted in colorectal cancer (DCC) gene expression levels can predict meningioma aggressiveness. Lower DCC expression in benign meningiomas may indicate a higher risk of tumor progression, aiding in early identification.

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

3.1K

Related Experiment Videos

Last Updated: Mar 22, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.0K
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

3.1K

Area of Science:

  • Neuro-oncology
  • Molecular Genetics
  • Cancer Biomarkers

Background:

  • Meningiomas are common primary brain tumors, with aggressive phenotypes occurring in a minority of cases.
  • Current stratification methods lack detailed molecular insights into predicting tumor aggressiveness.
  • Understanding the genetic drivers of meningioma progression is crucial for improved patient outcomes.

Purpose of the Study:

  • To investigate the molecular genetic basis of meningioma aggressiveness using whole transcript expression profiling.
  • To identify differentially expressed genes (DEGs) associated with meningioma grade and invasiveness.
  • To evaluate the potential of Deleted in colorectal cancer (DCC) as a biomarker for meningioma progression risk.

Main Methods:

  • Whole transcript expression profiling using microarrays on 14 meningioma samples (10 grade I, 4 grade II).
  • Differential gene expression analysis to identify DEGs between tumor groups.
  • Biofunctional analysis to predict upstream regulators and downstream effectors.
  • Comparative analysis based on sex and brain invasiveness.

Main Results:

  • Deleted in colorectal cancer (DCC) was identified as a key differentially expressed gene, enabling clustering into DCC expression groups.
  • Significant differences in gene expression were observed between DCC low and high expression groups (416 DEGs).
  • Key downregulated genes in low DCC expressors included DCC, PDE1C, OLFM2, GSTM5, PID1, SEMA6D, and INMT. Upregulated genes included C5orf63, HIPK2, and BHLHE40.
  • Biofunctional analysis implicated beta-estradiol, TGFB1, and dexamethasone as upstream regulators, and NFkB, PIK3R1, and CREBBP as downstream effectors.

Conclusions:

  • DCC expression levels show potential as a biomarker for identifying benign meningiomas at risk of progression.
  • Further research into the identified DEGs and regulatory pathways may elucidate mechanisms of meningioma aggressiveness.
  • Expression profiling provides valuable insights into the molecular heterogeneity of meningiomas.